At either 3 or 5 wk after inoculation, the mice were treated with equivalent tumor dose–depositing activities of 177Lu- or 225Ac-PSMA-617 alone or in combination (35 MBq of 177Lu, 40 kBq of 225Ac, or 17 MBq of 177Lu + 20 kBq 225Ac; 10/group). Here, FOLH1 is linked to neoplasm.